Panel: Reshoring Pharma Production at Scale

Session details:

The Trump administration's manufacturing renaissance has triggered the largest domestic pharmaceutical production buildup in decades, with major companies committing tens of billions to U.S. facilities. But transforming supply chains built over generations requires more than capital—it demands new strategic thinking about risk, resilience and competitive positioning. Industry executives will share their approaches to this historic reshoring effort and its implications for global pharmaceutical competition.